The most relevant news about our Group, in Argentina and around the world.

Exeltis acquires 100% of the turkish company Embil

Exeltis, a branch of the pharmaceutical Grupo Chemo, has acquired 100% of the Turkish pharmaceutical Embil.The deal is the biggest acquisition ever by Exeltis abroad.It also represents the entry of the Spanish company into Turkey, a market of great potential due to its population and its high proportion of young people (nearly a third are under 15 years of age).

The deal is part of Exeltis’s Strategic Plan that aims to consolidate its international development. Following its acquisitions in India, Indonesia and the United States, the company already has a presence in more than 40 countries, thanks to 30 subsidiaries in key markets and its extensive global manufacturing network in Europe, America and Asia.

Embil was founded 90 years ago. It is one of the largest pharmaceutical producers in Turkey, 16.6 million Euros net sales in 2013. It employs 200 workers and has two production plants located in the Turkish cities of Bomonti and Çerkezköy, the latter opened in 2012.

The integration of Embil in Exeltis leads to significant synergies, as it provides a significant complement for the company’s women’s health portfolio.With the incorporation of Embil, Exeltis expects to increase its turnover over the coming years.

Leandro Sigman, Managing Director of Grupo Chemo, explained that “This movement is a decisive step in the growth strategy of Exeltis as it responds to the company’s goal of international expansion, reinforcing our extensive product portfolio, which covers areas ranging from women’s health to dermatology and ophthalmology”.

Sigman also highlighted the value of Turkey as a key market for the pharmaceutical industry, with a population of over 80 million and 99% health coverage. That is why Exeltis has plans to undertake a number of investment projects in the country in the short term.

Following this operation, Grupo Chemo, with sales of over 1 billion dollars (785 million euros), has strengthened its international presence.Chemo is a Spanish corporation that has been active for more than 35 years at all levels of the chemical-pharmaceutical industry.

The Group’s activity is divided into three synergistic business areas:Industrial (Chemo), Brand (Exeltis) and Biotechnology (mAbxience). It has over 5,000 professionals in more than 40 countries on four continents, 10 manufacturing plants, nine specialised R&D centres, 12 branch offices and 33 affiliate pharmaceutical companies, with 1,150 clients in 96 countries around the world.

In addition, the Group recently strengthened its commitment to the Spanish market through its division mAbxience, which specialises in the development and manufacture of biosimilars, by acquiring 100% of the Genhelix biopharmaceutical plant (León).


About Exeltis

After more than two decades in the market, last year the brand ExeltisTM was created as a result of the sustained growth of the pharmaceutical business of the Chemo group brand.Exeltis thus combines the knowledge and experience of the group’s 35-plus years with innovative spirit, diversity and excellence as major values.With a presence in more than 40 countries, 4,000 employees, over 30 affiliates around the world, and a global manufacturing network in Europe, America and Asia, it is now an organisation with a great capacity to develop, produce and deliver treatment to millions of people around the world.



Top Story


Algunas aclaraciones sobre la vacuna | Hugo Sigman

Por Hugo Sigman En momentos en que la segunda ola de Covid se cobra más y más muertos, con muchas familias perdiendo a sus seres queridos y el sistema de salud muy estresado, la intoxicación de noticias falsas sólo contribuye … Continue reading


Latest News

News Mabxience

Hugo Sigman, sobre la vacuna de AstraZeneca: “Confiamos en que las pruebas serán exitosas”


News Grupo Insud Mundo Sano

El futuro de la pandemia visto por la bioquímica Silvia Gold: “Mucho de lo que aprendimos con dengue, creemos que es lo que hay que hacer con COVID-19″


News Grupo Insud

Hugo Sigman: “El único negocio que tengo con el Estado representa el 1,5% de mi facturación”


News Top Story Grupo Insud

Silvia Gold: “Las vacunas que más esperanza nos generan son las de vector viral”


News Top Story Mabxience

mAbxience: cómo es el laboratorio argentino que va a producir la vacuna de la Universidad de Oxford y AstraZeneca para América Latina


News Inmunova Top Story

ANMAT aprobó estudio clínico en humanos para el suero anti-Covid-19


News Grupo Insud

Startups con participación del CONICET se presentarán en BioArgentina 2021


News Grupo Insud

La OPS selecciona centros en Argentina y Brasil para desarrollar vacunas de ARNm contra la COVID-19